Cargando…
非小细胞肺癌切除组织中常用免疫组织化学指标尚不能预测远期生存
BACKGROUND AND OBJECTIVE: It has been drawn much attention to identify the molecular markers by immunohistochemistry (IHC) for evaluating the prognosis of non-small cell lung cancer (NSCLC) following resection. The aim of this study is to retrospectively associate ever tested IHC markers and prognos...
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
中国肺癌杂志编辑部
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5999823/ https://www.ncbi.nlm.nih.gov/pubmed/27009819 http://dx.doi.org/10.3779/j.issn.1009-3419.2016.03.05 |
_version_ | 1783331521629782016 |
---|---|
collection | PubMed |
description | BACKGROUND AND OBJECTIVE: It has been drawn much attention to identify the molecular markers by immunohistochemistry (IHC) for evaluating the prognosis of non-small cell lung cancer (NSCLC) following resection. The aim of this study is to retrospectively associate ever tested IHC markers and prognosis of NSCLC after resection. METHODS: A total of 722 NSCLC patients underwent surgery by single surgeon team from 2008 to 2013. Twelve molecular markers had been examined by IHC and the staining signals was re-scored with unified standard. Survival analysis by univariate and multivariate was carried out to assess the significance of these markers in prognosis of NSCLC in our prospective database with strict follow-up. RESULTS: The following twelve IHC markers had been tested between 2008 and 2013, including platelet-derived growth factor receptor (PDGFR)(n=124), excision repair cross complementing 1 (ERCC1)(n=124), epithelial growth factor receptor (EGFR)(n=131), vascular endothelial growth factor receptor 3 (VEGFR3)(n=142), NM23 (n=129), MRP (n=109), P170 (n=104), TS (n=143), Tubulin (n=133), ribonucleotide reductase M1 (RRM1)(n=131), ribonucleotide reductase M1 (COX2)(n=138), and TOPII (n=127). Only VEGFR3 expression was correlated with prognosis of the patients by univariate analysis, with 5-yrs survival rate being 77.6% and 65.0% (positive vs. negative) respectively (P=0.042). However, VEGFR3 was not an independent prognostic factor for this series of NSCLC patients in multivariate analysis. CONCLUSION: These twelve IHC markers could not predict prognosis of NSCLC patients after surgery in our series. |
format | Online Article Text |
id | pubmed-5999823 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | 中国肺癌杂志编辑部 |
record_format | MEDLINE/PubMed |
spelling | pubmed-59998232018-07-06 非小细胞肺癌切除组织中常用免疫组织化学指标尚不能预测远期生存 Zhongguo Fei Ai Za Zhi 临床研究 BACKGROUND AND OBJECTIVE: It has been drawn much attention to identify the molecular markers by immunohistochemistry (IHC) for evaluating the prognosis of non-small cell lung cancer (NSCLC) following resection. The aim of this study is to retrospectively associate ever tested IHC markers and prognosis of NSCLC after resection. METHODS: A total of 722 NSCLC patients underwent surgery by single surgeon team from 2008 to 2013. Twelve molecular markers had been examined by IHC and the staining signals was re-scored with unified standard. Survival analysis by univariate and multivariate was carried out to assess the significance of these markers in prognosis of NSCLC in our prospective database with strict follow-up. RESULTS: The following twelve IHC markers had been tested between 2008 and 2013, including platelet-derived growth factor receptor (PDGFR)(n=124), excision repair cross complementing 1 (ERCC1)(n=124), epithelial growth factor receptor (EGFR)(n=131), vascular endothelial growth factor receptor 3 (VEGFR3)(n=142), NM23 (n=129), MRP (n=109), P170 (n=104), TS (n=143), Tubulin (n=133), ribonucleotide reductase M1 (RRM1)(n=131), ribonucleotide reductase M1 (COX2)(n=138), and TOPII (n=127). Only VEGFR3 expression was correlated with prognosis of the patients by univariate analysis, with 5-yrs survival rate being 77.6% and 65.0% (positive vs. negative) respectively (P=0.042). However, VEGFR3 was not an independent prognostic factor for this series of NSCLC patients in multivariate analysis. CONCLUSION: These twelve IHC markers could not predict prognosis of NSCLC patients after surgery in our series. 中国肺癌杂志编辑部 2016-03-20 /pmc/articles/PMC5999823/ /pubmed/27009819 http://dx.doi.org/10.3779/j.issn.1009-3419.2016.03.05 Text en 版权所有©《中国肺癌杂志》编辑部2016 https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 3.0) License. See: https://creativecommons.org/licenses/by/3.0/ |
spellingShingle | 临床研究 非小细胞肺癌切除组织中常用免疫组织化学指标尚不能预测远期生存 |
title | 非小细胞肺癌切除组织中常用免疫组织化学指标尚不能预测远期生存 |
title_full | 非小细胞肺癌切除组织中常用免疫组织化学指标尚不能预测远期生存 |
title_fullStr | 非小细胞肺癌切除组织中常用免疫组织化学指标尚不能预测远期生存 |
title_full_unstemmed | 非小细胞肺癌切除组织中常用免疫组织化学指标尚不能预测远期生存 |
title_short | 非小细胞肺癌切除组织中常用免疫组织化学指标尚不能预测远期生存 |
title_sort | 非小细胞肺癌切除组织中常用免疫组织化学指标尚不能预测远期生存 |
topic | 临床研究 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5999823/ https://www.ncbi.nlm.nih.gov/pubmed/27009819 http://dx.doi.org/10.3779/j.issn.1009-3419.2016.03.05 |
work_keys_str_mv | AT fēixiǎoxìbāofèiáiqièchúzǔzhīzhōngchángyòngmiǎnyìzǔzhīhuàxuézhǐbiāoshàngbùnéngyùcèyuǎnqīshēngcún AT fēixiǎoxìbāofèiáiqièchúzǔzhīzhōngchángyòngmiǎnyìzǔzhīhuàxuézhǐbiāoshàngbùnéngyùcèyuǎnqīshēngcún AT fēixiǎoxìbāofèiáiqièchúzǔzhīzhōngchángyòngmiǎnyìzǔzhīhuàxuézhǐbiāoshàngbùnéngyùcèyuǎnqīshēngcún AT fēixiǎoxìbāofèiáiqièchúzǔzhīzhōngchángyòngmiǎnyìzǔzhīhuàxuézhǐbiāoshàngbùnéngyùcèyuǎnqīshēngcún AT fēixiǎoxìbāofèiáiqièchúzǔzhīzhōngchángyòngmiǎnyìzǔzhīhuàxuézhǐbiāoshàngbùnéngyùcèyuǎnqīshēngcún AT fēixiǎoxìbāofèiáiqièchúzǔzhīzhōngchángyòngmiǎnyìzǔzhīhuàxuézhǐbiāoshàngbùnéngyùcèyuǎnqīshēngcún AT fēixiǎoxìbāofèiáiqièchúzǔzhīzhōngchángyòngmiǎnyìzǔzhīhuàxuézhǐbiāoshàngbùnéngyùcèyuǎnqīshēngcún |